1Toh CK, Gao F, Lim WT, et al. Never-smokers with lung can- cer: epidemiologic evidence of a distinct disease entity. J Clin Onco12006; 24:2245-2251.
2Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Clin Onco12007; 25:561-570.
3Herbst RS, Lippman SM. Molecular signatures of lung cancer- -toward personalized therapy. N Engl J Med 2007; 356:76-78.
4Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsive- ness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139.
5Pao W, Miller VA. Epidermal growth factor receptor muta- tions, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Onco12005; 23:2556-2568.
6J Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-1500.
7Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fu- sion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008; 14:4275-4283.
8Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448:561-566.
9Sun Y, Ren Y, Fang Z, et al. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Onco12010; 28:4616-4620.
10Rikova K, Guo A, Zeng Q, et al. Global survey of phospho- tyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007; 131:1190-1203.
